Hao M. Bai

Anting, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Integrating multimodal ultrasound imaging and machine learning for predicting luminal and non-luminal breast cancer subtypes.

Integrating multimodal ultrasound imaging and machine learning for predicting luminal and non-luminal breast cancer subtypes.

Journal: Frontiers in oncology

Published: April 13, 2025

Prostaglandin G/H synthase 1 promotes thrombosis in atrial fibrillation through modulation of platelet activation, macrophage infiltration, inflammation, and autophagy inhibition.

Prostaglandin G/H synthase 1 promotes thrombosis in atrial fibrillation through modulation of platelet activation, macrophage infiltration, inflammation, and autophagy inhibition.

Journal: Acta cardiologica

Published: February 18, 2025

Safety and efficacy of multi-target TKI combined with nivolumab in check-point inhibitor-refractory patients with advanced NSCLC: a prospective, single-arm, two-stage study.

Safety and efficacy of multi-target TKI combined with nivolumab in check-point inhibitor-refractory patients with advanced NSCLC: a prospective, single-arm, two-stage study.

Journal: BMC cancer

Published: March 03, 2024

Genetic mutation profiling reveals biomarkers for targeted therapy efficacy and prognosis in non-small cell lung cancer.

Genetic mutation profiling reveals biomarkers for targeted therapy efficacy and prognosis in non-small cell lung cancer.

Journal: Heliyon

Published: October 16, 2023

Genetic alterations predict poor efficacy, outcomes and resistance to second-line osimertinib treatment in non-small cell lung cancer.

Genetic alterations predict poor efficacy, outcomes and resistance to second-line osimertinib treatment in non-small cell lung cancer.

Journal: American journal of cancer research

Published: October 10, 2023

mTOR pathway gene mutations predict response to immune checkpoint inhibitors in multiple cancers.

mTOR pathway gene mutations predict response to immune checkpoint inhibitors in multiple cancers.

Journal: Journal of translational medicine

Published: February 03, 2022

Novel ETV1 mutation in small cell lung cancer transformation resistant to EGFR tyrosine kinase inhibitors.

Novel ETV1 mutation in small cell lung cancer transformation resistant to EGFR tyrosine kinase inhibitors.

Journal: Annals of translational medicine

Published: April 27, 2021

Efficacy of erlotinib as neoadjuvant regimen in EGFR-mutant locally advanced non-small cell lung cancer patients.

Efficacy of erlotinib as neoadjuvant regimen in EGFR-mutant locally advanced non-small cell lung cancer patients.

Journal: The Journal of international medical research

Published: December 31, 2019

Detection of EGFR mutations using target capture sequencing in plasma of patients with non-small-cell lung cancer.

Detection of EGFR mutations using target capture sequencing in plasma of patients with non-small-cell lung cancer.

Journal: Journal of clinical pathology

Published: January 03, 2019

Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2) EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Prospective, Single-Arm, Phase II Study.

Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2) EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Prospective, Single-Arm, Phase II Study.

Journal: The oncologist

Published: February 28, 2018

The effectiveness of EGFR-TKIs against brain metastases in EGFR mutation-positive non-small-cell lung cancer.

The effectiveness of EGFR-TKIs against brain metastases in EGFR mutation-positive non-small-cell lung cancer.

Journal: OncoTargets and therapy

Published: May 12, 2017

Mimicking the BIM BH3 domain overcomes resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer.

Mimicking the BIM BH3 domain overcomes resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer.

Journal: Oncotarget

Published: November 30, 2016

Showing 1-12 of 21

Last Updated: 09/26/2026